BACKGROUND: Common single nucleotide polymorphisms at chromosome 4q25 (rs2200733, rs10033464) are associated with both lone and typical atrial fibrillation (AF). Risk alleles at 4q25 have recently been shown to predict recurrence of AF after ablation in a population of predominately lone AF, but lone AF represents only 5%-30% of AF cases. OBJECTIVE: To test the hypothesis that 4q25 AF risk alleles can predict response to AF ablation in the majority of AF cases. METHODS: Patients enrolled in the Vanderbilt AF Registry underwent 378 catheter-based AF ablations (median age 60 years; 71% men; 89% typical AF) between 2004 and 2011. The primary end point was time to recurrence of any nonsinus atrial tachyarrhythmia (atrial tachycardia, atrial flutter, or AF). RESULTS: Two-hundred atrial tachycardia, atrial flutter, or AF recurrences (53%) were observed. In multivariable analysis, the rs2200733 risk allele predicted a 24% shorter recurrence-free time (survival time ratio 0.76; 95% confidence interval [CI] 0.6-0.95; P = .016) compared with wild type. The heterozygous haplotype demonstrated a 21% shorter recurrence-free time (survival time ratio 0.79; 95% CI 0.62-0.99) and the homozygous risk allele carriers a 39% shorter recurrence-free time (survival time ratio 0.61; 95% CI 0.37-1.0; P = .037). CONCLUSIONS: Risk alleles at the 4q25 loci predict impaired clinical response to AF ablation in a population of patients with predominately typical AF. Our findings suggest that the rs2200733 polymorphism may hold promise as an objectively measured patient characteristic that can be used as a clinical tool for selecting patients for AF ablation.
BACKGROUND: Common single nucleotide polymorphisms at chromosome 4q25 (rs2200733, rs10033464) are associated with both lone and typical atrial fibrillation (AF). Risk alleles at 4q25 have recently been shown to predict recurrence of AF after ablation in a population of predominately lone AF, but lone AF represents only 5%-30% of AF cases. OBJECTIVE: To test the hypothesis that 4q25 AF risk alleles can predict response to AF ablation in the majority of AF cases. METHODS:Patients enrolled in the Vanderbilt AF Registry underwent 378 catheter-based AF ablations (median age 60 years; 71% men; 89% typical AF) between 2004 and 2011. The primary end point was time to recurrence of any nonsinus atrial tachyarrhythmia (atrial tachycardia, atrial flutter, or AF). RESULTS: Two-hundred atrial tachycardia, atrial flutter, or AF recurrences (53%) were observed. In multivariable analysis, the rs2200733 risk allele predicted a 24% shorter recurrence-free time (survival time ratio 0.76; 95% confidence interval [CI] 0.6-0.95; P = .016) compared with wild type. The heterozygous haplotype demonstrated a 21% shorter recurrence-free time (survival time ratio 0.79; 95% CI 0.62-0.99) and the homozygous risk allele carriers a 39% shorter recurrence-free time (survival time ratio 0.61; 95% CI 0.37-1.0; P = .037). CONCLUSIONS: Risk alleles at the 4q25 loci predict impaired clinical response to AF ablation in a population of patients with predominately typical AF. Our findings suggest that the rs2200733 polymorphism may hold promise as an objectively measured patient characteristic that can be used as a clinical tool for selecting patients for AF ablation.
Authors: Jun Wang; Elzbieta Klysik; Subeena Sood; Randy L Johnson; Xander H T Wehrens; James F Martin Journal: Proc Natl Acad Sci U S A Date: 2010-05-10 Impact factor: 11.205
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Patrick T Ellinor; Kathryn L Lunetta; Nicole L Glazer; Arne Pfeufer; Alvaro Alonso; Mina K Chung; Moritz F Sinner; Paul I W de Bakker; Martina Mueller; Steven A Lubitz; Ervin Fox; Dawood Darbar; Nicholas L Smith; Jonathan D Smith; Renate B Schnabel; Elsayed Z Soliman; Kenneth M Rice; David R Van Wagoner; Britt-M Beckmann; Charlotte van Noord; Ke Wang; Georg B Ehret; Jerome I Rotter; Stanley L Hazen; Gerhard Steinbeck; Albert V Smith; Lenore J Launer; Tamara B Harris; Seiko Makino; Mari Nelis; David J Milan; Siegfried Perz; Tõnu Esko; Anna Köttgen; Susanne Moebus; Christopher Newton-Cheh; Man Li; Stefan Möhlenkamp; Thomas J Wang; W H Linda Kao; Ramachandran S Vasan; Markus M Nöthen; Calum A MacRae; Bruno H Ch Stricker; Albert Hofman; André G Uitterlinden; Daniel Levy; Eric Boerwinkle; Andres Metspalu; Eric J Topol; Aravinda Chakravarti; Vilmundur Gudnason; Bruce M Psaty; Dan M Roden; Thomas Meitinger; H-Erich Wichmann; Jacqueline C M Witteman; John Barnard; Dan E Arking; Emelia J Benjamin; Susan R Heckbert; Stefan Kääb Journal: Nat Genet Date: 2010-02-21 Impact factor: 38.330
Authors: M Benjamin Shoemaker; Daniela Husser; Carolina Roselli; Meelad Al Jazairi; Jonathan Chrispin; Michael Kühne; Benjamin Neumann; Stacey Knight; Han Sun; Sanghamitra Mohanty; Christian Shaffer; Sébastien Thériault; Lauren Lee Rinke; Joylene E Siland; Diane M Crawford; Laura Ueberham; Omeed Zardkoohi; Petra Büttner; Bastiaan Geelhoed; Steffen Blum; Stefanie Aeschbacher; Jonathan D Smith; David R Van Wagoner; Rebecca Freudling; Martina Müller-Nurasyid; Jay Montgomery; Zachary Yoneda; Quinn Wells; Tariq Issa; Peter Weeke; Victoria Jacobs; Isabelle C Van Gelder; Gerhard Hindricks; John Barnard; Hugh Calkins; Dawood Darbar; Greg Michaud; Stefan Kääb; Patrick Ellinor; Andrea Natale; Mina Chung; Saman Nazarian; Michael J Cutler; Moritz F Sinner; David Conen; Michiel Rienstra; Andreas Bollmann; Dan M Roden; Steven Lubitz Journal: Circ Arrhythm Electrophysiol Date: 2020-02-14
Authors: Jason D Roberts; Jonathan C Hsu; Bradley E Aouizerat; Clive R Pullinger; Mary J Malloy; John P Kane; Jeffrey E Olgin; Gregory M Marcus Journal: J Cardiovasc Electrophysiol Date: 2013-12-13